Allspring Global Investments Holdings LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 14.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 181,122 shares of the company’s stock after selling 29,409 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.47% of Tarsus Pharmaceuticals worth $10,029,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC grew its holdings in Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after acquiring an additional 3,379 shares during the last quarter. Creative Planning acquired a new position in shares of Tarsus Pharmaceuticals during the third quarter worth approximately $362,000. Assenagon Asset Management S.A. grew its stake in shares of Tarsus Pharmaceuticals by 7.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after purchasing an additional 77,825 shares during the last quarter. E. Ohman J or Asset Management AB increased its holdings in shares of Tarsus Pharmaceuticals by 20.5% in the third quarter. E. Ohman J or Asset Management AB now owns 46,981 shares of the company’s stock valued at $1,545,000 after purchasing an additional 8,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Tarsus Pharmaceuticals by 64.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock worth $241,000 after purchasing an additional 2,879 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.
Tarsus Pharmaceuticals Stock Up 1.3 %
Shares of Tarsus Pharmaceuticals stock opened at $50.85 on Wednesday. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The business’s 50 day simple moving average is $52.06 and its 200 day simple moving average is $42.19. The firm has a market cap of $1.94 billion, a PE ratio of -13.35 and a beta of 1.01.
Analyst Ratings Changes
View Our Latest Research Report on Tarsus Pharmaceuticals
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
See Also
- Five stocks we like better than Tarsus Pharmaceuticals
- Differences Between Momentum Investing and Long Term Investing
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Which Wall Street Analysts are the Most Accurate?
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report).
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.